BGB-A445

BGB-A445 is a humanized non-ligand-blocking agonistic OX40 monoclonal antibody with high affinity to OX40. BGB-A445 activates downstream NF-κB pathway to induce immune cell activation, proliferation, and survival. BGB-A445 dose-dependently and significantly depletes regulatory T cells via antibody-dependent cellular cytotoxicity (ADCC) . BGB-A445 demonstrates robust and dose-dependent antitumor efficacy in the MC38 mice models. BGB-A445 can be used for the research of cancer, such as colon adenocarcinoma[1][2].

3033874-57-3

12352203

NF-κB; Orexin Receptor (OX Receptor)

GPCR/G Protein; Neuronal Signaling; NF-κB

Cancer-programmed cell death

Cancer

[1]Jiang B, et al. BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models. Front Med. 2023 Dec;17 (6) :1170-1185.|[2]Jiang B, et al. A differentiated anti-OX40 agonist BGB-A445 does not block OX40-OX40L interaction and reveals remarkable anti-tumor efficacy in preclinical models.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P991613/

Inhibitory Antibodies

No Development Reported